As of 2026-10-15, the Relative Valuation of CytomX Therapeutics Inc (CTMX) is (7.49) USD. This relative valuation is based on P/E multiples. With the latest stock price at 2.23 USD, the upside of CytomX Therapeutics Inc based on Relative Valuation is -435.9%.
The range of the Relative Valuation is (5.19) - (8.46) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 14.2x - 23.1x | 20.0x |
| Forward P/E multiples | 12.6x - 26.7x | 21.0x |
| Fair Price | (5.19) - (8.46) | (7.49) |
| Upside | -332.7% - -479.3% | -435.9% |
| Date | P/E |
| 2026-10-13 | -6.35 |
| 2026-10-12 | -6.61 |
| 2026-10-09 | -7.02 |
| 2026-10-08 | -6.75 |
| 2026-10-07 | -6.97 |
| 2026-10-06 | -7.00 |
| 2026-10-05 | -7.05 |
| 2026-10-02 | -7.00 |
| 2026-10-01 | -7.19 |
| 2026-09-30 | -7.43 |
| 2026-09-29 | -7.52 |
| 2026-09-28 | -7.35 |
| 2026-09-25 | -7.38 |
| 2026-09-24 | -7.52 |
| 2026-09-23 | -7.60 |
| 2026-09-22 | -8.04 |
| 2026-09-21 | -7.54 |
| 2026-09-18 | -7.54 |
| 2026-09-17 | -7.71 |
| 2026-09-16 | -7.56 |
| 2026-09-15 | -7.35 |
| 2026-09-14 | -8.75 |
| 2026-09-11 | -8.99 |
| 2026-09-10 | -9.16 |
| 2026-09-09 | -9.68 |
| 2026-09-08 | -9.98 |
| 2026-09-04 | -10.14 |
| 2026-09-03 | -10.06 |
| 2026-09-02 | -10.17 |
| 2026-09-01 | -10.03 |
| 2026-08-31 | -9.18 |
| 2026-08-28 | -8.77 |
| 2026-08-27 | -9.35 |
| 2026-08-26 | -9.07 |
| 2026-08-25 | -9.21 |
| 2026-08-24 | -8.99 |
| 2026-08-21 | -8.96 |
| 2026-08-20 | -8.99 |
| 2026-08-19 | -9.76 |
| 2026-08-18 | -9.27 |
| 2026-08-17 | -9.43 |
| 2026-08-14 | -9.18 |
| 2026-08-13 | -9.16 |
| 2026-08-12 | -9.54 |
| 2026-08-11 | -9.43 |
| 2026-08-10 | -9.40 |
| 2026-08-07 | -9.46 |
| 2026-08-06 | -9.21 |
| 2026-08-05 | -9.16 |
| 2026-08-04 | -9.07 |